http://orcid.org/0000-0002-0880-8501
References
- Smith J, Andes D. Therapeutic drug monitoring of antifungals: pharmacokinetic and pharmacodynamics considerations. Ther Drug Monit. 2008;30:167–72.10.1097/FTD.0b013e318167d0e0
- Matsumoto K, Ikawa K, Abematsu A, Fukunaga N, Nishida K, Fukamizu T, et al. Correlation between voriconazole trough plasma concentration and hepatotoxicity in patients with different CYP2C19 genotypes. Int J Antimicrob Agents. 2009;34:91–4.10.1016/j.ijantimicag.2009.01.008
- Zonios D, Yamazaki H, Murayama N, Natarajan V, Palmore T, Childs R, et al. Voriconazole metabolism, toxicity, and the effect of cytochrome P450 2C19 genotype. J Infect Dis. 2014;209:1941–8.10.1093/infdis/jiu017
- Pascual A, Calandra T, Bolay S, Buclin T, Bille J, Marchetti O. Voriconazole drug therapeutic monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis. 2008;46:928–30.
- Kim KH, Lee S, Lee SW, Yun NR, Kim NJ, Yu KS, et al. Voriconazole-associated severe hyponatremia. Med Mycol. 2012;50:103–5.10.3109/13693786.2011.587210
- Xu RA, Lin GY, Hu LF, Shi DW, Ye XI, Liu YJ, et al. Successful Management of voriconazole-associated hyponatremia with therapeutic drug monitoring. Antimicrob Agents and Chemother. 2013;57:2422–3.10.1128/AAC.00146-13
- Najanro CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239–45.
- MIMS Online [Internet]. St Leonards: MIMS Australia; 2015 [November 1]. Available from: https://www.mimsonline.com.au/Search/Search.aspx.
- Teranishi J, Nagatoya K, Kakita T, Yamauchi Y, Matsuda H, Mori T, et al. Voriconazole-associated salt-losing nephropathy. Clin Exp Nephrol. 2010;14:377–80.10.1007/s10157-010-0305-0
- Teusink A, Vinks A, Zhang K, Davies S, Fukuda T, Lane A, et al. Genotype-directed dosing leads to optimized voriconazole levels in pediatric patients receiving hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2015;22(3):482–6.